São Paulo, August 2023 - Eurofarma and the English consultancy IN-PART have closed, for the second consecutive year, a partnership that seeks academic groups for the development of projects in the field of antimicrobials. The main objective is for these research communities to be able to present initiatives at an early or advanced stage for the discovery of small antimicrobial molecules of natural origin, potential for the development of highly innovative medicines.

This action reinforces Eurofarma's pillar of innovation, to expand its activities in the advancement and co-development of molecules and medicines that bring radical innovations in their conception. For 2023, the company plans to invest BRL 700 million in Research & Development and currently has 1,800 of its own molecules.

After the end of the registration period, which runs until August 21, IN-PART will analyze all the projects with greater potential to then start a more in-depth development together with Eurofarma.

To apply, applicants must include a 200-300 word summary of the project, detailing the most relevant aspects. Publicly available information such as articles, conference slides or academic profiles are also accepted for application.

Click here to learn more and sign up.

About the Eurofarma Group

Founded in 1972, Eurofarma operates in the health sector with the production and sale of products and services to improve people's quality of life. With a focus on generating shared value, it covers all major pharmaceutical segments such as Prescription, Generics, OTC, Hospital and Oncology. With broad coverage of therapeutic classes, the portfolio in the region comprises 2,800 SKUs and serves 42 medical specialties.

Present in 22 countries, mainly in Latin America, Eurofarma also has operations in the USA and Africa. With more than 11,000 employees, in 2022 it became a publicly traded company registered with the Brazilian Securities Commission (CVM). Reported net revenue was R$8 billion, an increase of 13.3% over the previous year, with R$2 billion in EBITDA, an increase of 20%. In R&D, investments in the year totaled more than R$590 million, equivalent to 7.4% of net revenue.

Eurofarma on social networks

Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | Twitter: @eurofarma
Youtube: @eurofarmalab

Press Information

G&A – Public Relations
Luciana Lima - 11 98596-9601 – luciana.lima@gaspar.com.br
Sarah Cardoso - 11 94821-0883 - sarah.cardoso@gaspar.com.br
Guilherme Gaspar - 11 98285-6000 - guilherme@gaspar.com.br